Evolocumab + Placebo

Phase 1Recruiting

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Abdominal Aortic Aneurysm

Conditions

Abdominal Aortic Aneurysm

Trial Timeline

Jul 1, 2026 → Feb 28, 2028

NCT ID

NCT06081153

About Evolocumab + Placebo

Evolocumab + Placebo is a phase 1 stage product being developed by Amgen for Abdominal Aortic Aneurysm. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06081153. Target conditions include Abdominal Aortic Aneurysm.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06081153	Phase 1	Recruiting	Jul 1, 2026	Feb 28, 2028	Abdominal Aortic Aneurysm
NCT03872401	Phase 3	Completed	Jun 11, 2019	Jul 25, 2025	Coronary Heart Disease (CHD)
NCT03433755	Phase 3	Terminated	May 9, 2019	May 9, 2020	Primary Hypercholesterolemia
NCT03515304	Phase 2	Completed	May 20, 2018	Mar 25, 2025	Acute Coronary Syndrome
NCT02833844	Phase 3	Completed	May 22, 2017	Jan 27, 2020	Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
NCT02729025	Phase 3	Completed	Apr 14, 2016	Apr 5, 2018	Subjects With Hyperlipidemia, Dyslipidemia
NCT02392559	Phase 3	Completed	Mar 24, 2016	Nov 25, 2019	Heterozygous Familial Hypercholesterolemia
NCT01813422	Phase 3	Completed	Apr 18, 2013	Jul 29, 2016	Hypercholesterolemia
NCT01764633	Phase 3	Completed	Feb 8, 2013	Nov 11, 2016	Dyslipidemia
NCT01763918	Phase 3	Completed	Feb 7, 2013	Dec 19, 2013	Hyperlipidemia
NCT01588496	Phase 2/3	Completed	Apr 5, 2012	Jan 31, 2014	Homozygous Familial Hypercholesterolemia
NCT01375751	Phase 2	Completed	Aug 2, 2011	May 16, 2012	Hypercholesterolemia, Familial
NCT01133522	Phase 1	Completed	Jun 1, 2010	Sep 14, 2011	Hyperlipidemia

Competing Products

20 competing products in Abdominal Aortic Aneurysm

See all competitors

Product	Company	Stage	Hype Score
PD-1 Inhibitors + Irinotecan + Capecitabine tablets	Jiangsu Hengrui Medicine	Phase 3	77
HR021618 + Placebo	Jiangsu Hengrui Medicine	Phase 2	52
Ticagrelor + Placebo	AstraZeneca	Phase 2	52
Relebactam 250 mg + Relebactam 125 mg + Imipenem/cilastatin + Matching placebo to relebactam	Merck	Phase 2	52
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo	Merck	Phase 3	77
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mg	Merck	Phase 3	77
CXA-201 and metronidazole + Meropenem	Merck	Phase 3	77
Imipenem+Cilastatin/Relebactam	Merck	Phase 3	77
CXA-101/ tazobactam and metronidazole + meropenem plus saline placebo	Merck	Phase 2	52
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for Metronidazole	Merck	Phase 2	52
Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet	Merck	Phase 2/3	65
Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks + MK0826, /Duration of Treatment : 8 Weeks + Comparator: metronidazole / Duration of Treatment: 8 Weeks	Merck	Phase 3	77
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazole	Merck	Approved	85
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks	Merck	Phase 3	77
LYS228 + Standard of care therapy	Novartis	Phase 2	52
ACZ885 + Placebo	Novartis	Phase 2	52
tigecycline	Pfizer	Phase 3	76
recombinant human growth hormone	Pfizer	Phase 3	76
Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks + Placebo first followed by open label pregabalin	Pfizer	Approved	84
Ceftazidime-avibactam + metronidazole + Meropenem	Pfizer	Phase 3	76

Other Products from Amgen